Based on the potential importance of CcnD1 as a clinical target, and the strong anti-tumor effects of Gltn seen in preclinical models of triple-negative breast and cholangiocarcinoma, we suggest that Gltn should be considered for clinical trials as an anti-cancer agent. The gene discussed is CCND1; the disease is neoplasm.